{"entity":{"id":"nct07480356","kind":"trial","name":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","aka":[],"tldr":"A phase 3 trial testing TARA-002 in bladder & urothelial cancer, now recruiting.","summary":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer is a phase 3 interventional study registered as NCT07480356, led by Protara Therapeutics, and recruiting on the registry. Official title: A Phase 3, Randomised Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer. Planned enrolment is 284 participants (estimated). The study started in 2026-05-29 and primary completion is expected in 2028-04. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07480356","url":"https://clinicaltrials.gov/study/NCT07480356"}],"tags":["ctgov-ingest"],"related":[],"cancers":["urothelial","non-muscle-invasive-bladder-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tara-002"],"companies":["protara-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07480356","phase":"3","setting":"A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer","sponsor":"Protara Therapeutics","participation":[{"nct":"NCT07480356","source":"https://clinicaltrials.gov/study/NCT07480356","fetchedAt":"2026-10-07T16:55:46.774Z","studySha256":"cf695fc505d40d7ff53ef434e19a08e3a3977250f53c24f8a74387ce7a109240","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Protara Therapeutics","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":284,"enrolmentType":"ESTIMATED","siteCount":11,"recruitingSiteCount":11,"countries":["Ukraine","United States"]}],"started":"2026-05-29","startedType":"actual","enrolled":284,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07480356/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/"}],"drug":[{"id":"tara-002","kind":"drug","name":"TARA-002","route":"/drugs/tara-002/"}],"company":[{"id":"protara-therapeutics","kind":"company","name":"Protara Therapeutics","route":"/companies/protara-therapeutics/"}]}}